Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells.

Tomotaka KatoHiroaki OnoMikiya FujiiKeiichi AkahoshiToshiro OguraKosuke OgawaDaisuke BanAtsushi KudoShinji TanakaMinoru Tanabe

Published in: PloS one (2021)

Cytoplasmic RRM1 activation is involved in biological processes related to drug resistance in response to gemcitabine exposure and could be a potential target for pancreatic cancer treatment.

Keyphrases

liver failure
locally advanced
drug induced
respiratory failure
squamous cell carcinoma
aortic dissection
combination therapy
risk assessment
climate change
hepatitis b virus
replacement therapy